- Home
- IMUX vs BYSI Comparison
IMUX vs BYSI Comparison
Compare IMUX & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- BYSI
- Stock Information
- Founded
- IMUX 2016
- BYSI 2010
- Country
- IMUX United States
- BYSI United States
- Employees
- IMUX N/A
- BYSI N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- IMUX Health Care
- BYSI Health Care
- Exchange
- IMUX Nasdaq
- BYSI Nasdaq
- Market Cap
- IMUX 67.8M
- BYSI 71.0M
- IPO Year
- IMUX N/A
- BYSI 2017
- Fundamental
- Price
- IMUX $0.96
- BYSI $2.03
- Analyst Decision
- IMUX Strong Buy
- BYSI
- Analyst Count
- IMUX 5
- BYSI 0
- Target Price
- IMUX $7.50
- BYSI N/A
- AVG Volume (30 Days)
- IMUX 1.1M
- BYSI 25.2K
- Earning Date
- IMUX 08-11-2025
- BYSI 08-11-2025
- Dividend Yield
- IMUX N/A
- BYSI N/A
- EPS Growth
- IMUX N/A
- BYSI N/A
- EPS
- IMUX N/A
- BYSI N/A
- Revenue
- IMUX N/A
- BYSI N/A
- Revenue This Year
- IMUX N/A
- BYSI N/A
- Revenue Next Year
- IMUX N/A
- BYSI N/A
- P/E Ratio
- IMUX N/A
- BYSI N/A
- Revenue Growth
- IMUX N/A
- BYSI N/A
- 52 Week Low
- IMUX $0.56
- BYSI $0.98
- 52 Week High
- IMUX $2.11
- BYSI $3.44
- Technical
- Relative Strength Index (RSI)
- IMUX 55.60
- BYSI 44.54
- Support Level
- IMUX $0.94
- BYSI $1.87
- Resistance Level
- IMUX $1.18
- BYSI $2.13
- Average True Range (ATR)
- IMUX 0.08
- BYSI 0.15
- MACD
- IMUX 0.01
- BYSI -0.02
- Stochastic Oscillator
- IMUX 40.95
- BYSI 43.10
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.